Application of immune combination therapy in MSS/pMMR-type colorectal cancer: current status and future perspectives
10.3760/cma.j.cn112152-20230904-00116
- VernacularTitle:微卫星稳定/错配修复完整型结直肠癌的免疫联合治疗进展
- Author:
Xiaoling ZHANG
1
;
Wenxuan FAN
;
Yunyi DU
;
Yan ZHANG
;
Fei SU
;
Wenqing HU
;
Jun ZHAO
Author Information
1. 山西省长治市人民医院肿瘤内科，长治046000
- Keywords:
Colorectal neoplasms;
Immune checkpoint inhibitors;
Microsatellite stability;
Mismatch repair proficiency;
Immunotherapy
- From:
Chinese Journal of Oncology
2024;46(8):725-736
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immune checkpoint inhibitors (ICIs) have been widely used in malignant solid tumors with remarkable efficacy. However, in colorectal cancer (CRC), ICIs have shown significant therapeutic effects only in patients with highly microsatellite unstable/mismatch repair-deficient metastatic CRC and these patients are only a minority of all CRC patients. In contrast, the majority of patients, those with microsatellite stable (MSS)/mismatch repair-complete (pMMR)-type metastatic CRC, could hardly benefit from ICI monotherapies, and immune combination therapies have become the key to solveing this clinical challenge. This article introduces the common patterns and possible mechanisms of immune-combination therapies for MSS/pMMR-type CRC, the exploration and progress made in the application of immune-combination therapies, as well as the possible predictive markers of efficacy of immune therapies. The prospects and directions of ICIs in the treatment of MSS/pMMR-type CRC are also discussed.
